Clinical Trial Update: US Selumetinib Registry

View source ↗

Summary

The US Selumetinib registry trial for Neurofibromatosis Type 1 with plexiform neurofibromas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibromas

Drugs mentioned

• Koselugo (selumetinib)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neurofibromatosis Type 1, Plexiform Neurofibromas | Status: TERMINATED